Simin Wang, Yangjie Xiong, Yuxiang Luo, Yanying Shen, Fengrui Zhang, Haoqi Lan, Yuzhi Pang, Xiaofang Wang, Xiaoqi Li, Xufen Zheng, Xiaojing Lu, Xiaoxiao Liu, Yumei Cheng, Tanwen Wu, Yue Dong, Yuan Lu, Jiujie Cui, Xiaona Jia, Sheng Yang, Liwei Wang, Yuexiang Wang
Pancreatic ductal adenocarcinoma (PDAC) is a devastating disease with an overall 5-year survival rate of <12% due to the lack of effective treatments. Novel treatment strategies are urgently needed. Here, PKMYT1 is identified through genome-wide CRISPR screens as a non-mutant, genetic vulnerability of PDAC. Higher PKMYT1 expression levels indicate poor prognosis in PDAC patients. PKMYT1 ablation inhibits tumor growth and proliferation in vitro and in vivo by regulating cell cycle progression and inducing apoptosis...
April 3, 2024: EMBO Molecular Medicine